Faisal Saud Dar, Abu Bakar Hafeez Bhatti, Abdul‐Wahab Dogar, Haseeb Zia, Sadaf Amin, Atif Rana, Rashid Nazer, Nasir Ayub Khan, Etizaz‐ud‐din Khan, Muhammad Zameer Rajput, Muhammad Salih, Najmul Hassan Shah – 17 April 2015 – Living donor liver transplantation (LDLT) is the only treatment option for patients with end‐stage liver disease (ESLD) where cadaveric donors are not available. In developing countries, the inception of LDLT programs remains a challenge. The first successful liver transplantation program in Pakistan started transplantation in 2012.

Lynn A. Fussner, Julie K. Heimbach, Chun Fan, Ross Dierkhising, Elizabeth Coss, Michael D. Leise, Kymberly D. Watt – 16 April 2015 – The evolution of metabolic and cardiovascular disease (CVD) complications after liver transplantation (LT) is poorly characterized. We aim to illustrate the prevalence of obesity and metabolic syndrome (MS), define the cumulative incidence of CVD, and characterize risk factors associated with these comorbidities after LT. A retrospective review of 455 consecutive LT recipients from 1999 to 2004 with an 8‐ to 12‐year follow‐up was performed.

Thierry Gustot, Javier Fernandez, Elisabet Garcia, Filippo Morando, Paolo Caraceni, Carlo Alessandria, Wim Laleman, Jonel Trebicka, Laure Elkrief, Corinna Hopf, Pablo Solís‐Munoz, Faouzi Saliba, Stefan Zeuzem, Augustin Albillos, Daniel Benten, José Luis Montero‐Alvarez, Maria Teresa Chivas, Mar Concepción, Juan Córdoba, Aiden McCormick, Rudolf Stauber, Wolfgang Vogel, Andrea de Gottardi, Tania M.

Yael R. Nobel, Kimberly A. Forde, Linda Wood, Katarzyna Cartiera, Armando S. Munoz‐Abraham, Peter S. Yoo, Peter L. Abt, David S. Goldberg – 11 April 2015 – Living donor liver transplantation (LDLT) is a comparable alternative to deceased donor liver transplantation and can mitigate the risk of dying while waiting for transplant. Although evidence exists of decreased utilization of living donor kidney transplants among racial minorities, little is known about access to LDLT among racial/ethnic minorities.

Katharina Esser‐Nobis, Christian Harak, Philipp Schult, Yuri Kusov, Volker Lohmann – 11 April 2015 – Hepatitis A virus (HAV) and hepatitis C virus (HCV) are two positive‐strand RNA viruses sharing a similar biology, but causing opposing infection outcomes, with HAV always being cleared and HCV establishing persistence in the majority of infections. To gain deeper insight into determinants of replication, persistence, and treatment, we established a homogenous cell‐culture model allowing a thorough comparison of RNA replication of both viruses.

Umberto Baccarani, Riccardo Pravisani, Gian Luigi Adani, Dario Lorenzin, Vittorio Cherchi, Pierluigi Toniutto, Andrea Risaliti – 11 April 2015

Julie Heimbach, Eleonora Terzi – 10 April 2015

Kenneth Hung, Jane Gralla, Jennifer L. Dodge, Kiran M. Bambha, Melisa Dirchwolf, Hugo R. Rosen, Scott W. Biggins – 10 April 2015 – Repeat liver transplantation (LT) is controversial because of inferior outcomes versus primary LT. A minimum 1‐year expected post–re‐LT survival of 50% has been proposed. We aimed to identify combinations of Model for End‐Stage Liver Disease (MELD), donor risk index (DRI), and recipient characteristics achieving this graft survival threshold.

Aurelie Gineste, Patricia Martin, Eric Oswald, Hélène Coppin, Marie‐Paule Roth – 10 April 2015

Dechun Feng, Mingjiang Xu, Bin Gao – 10 April 2015